Incidence and predictors of tenofovir disoproxil fumarate-induced renal impairment in HIV infected Nigerian patients

被引:10
|
作者
Ojeh, Bazim V. [1 ]
Abah, Isaac O. [2 ]
Ugoagwu, Placid [1 ]
Agaba, Patricia A. [3 ]
Agbaji, Oche O. [4 ]
Gyang, Steven S. [5 ]
机构
[1] Jos Univ, Teaching Hosp, AIDS Prevent Initiat Nigeria APIN, PMB 2076, Jos, Nigeria
[2] Jos Univ, Teaching Hosp, Pharm Dept, PMB 2076, Jos, Nigeria
[3] Univ Jos, Dept Family Med, PMB 2084, Jos, Nigeria
[4] Univ Jos, Jos Univ Teaching Hosp, Dept Med, PMB 2076, Jos, Nigeria
[5] Univ Jos, Dept Pharmacol, PMB 2084, Jos, Nigeria
来源
GERMS | 2018年 / 8卷 / 02期
关键词
Renal impairment; TDF; nephrotoxicity; antiretroviral agents;
D O I
10.18683/germs.2018.1133
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction The use of tenofovir disoproxil fumarate (TDF) in the treatment of HIV infection has been associated with renal dysfunction. In Nigeria, data on the incidence and risk factors of TDF nephrotoxicity is sparse. We determined the cumulative incidence of and risk factors for TDF-induced renal impairment in HIV-infected individuals accessing care at the antiretroviral therapy (ART) clinic of Jos University Teaching Hospital, Nigeria. Methods This retrospective cohort analysis included patients aged 16 years that initiated ART between January 2008 and December 2011. Renal impairment, defined as glomerular filtration rate GFR <60 mL/min/1.73 sqm using the Modification of Diet in Renal Disease (MDRD) equation was assessed at baseline and at 48 weeks on ART. Logistic regression was performed to determine factors associated with incident renal impairment. Results The mean age was 39 +/- 9 years, and 67.1% were female. The cumulative incidence of renal impairment among the TDF-exposed and TDF-unexposed groups was 4.6% and 2.3% respectively (p<0.001). TDF exposure was significantly associated with renal impairment [OR=2.0, 95%CI=(1.48-2.89), p<0.001] in bivariate analysis. In multivariate analysis, older age (aOR=1.06, 95%CI=(1.05-1.08), p<0.001), TDF exposure [aOR=1.85, 95%CI=(1.31-2.60), p<0.001] and co-morbidities [aOR=2.71, 95%CI=(1.72-4.25), p<0.001] were significantly associated with renal impairment. Conclusion TDF exposure, aging and comorbidities were predictors of renal toxicity among HIV positive patients. Regular monitoring of renal function in such high-risk individuals is recommended.
引用
收藏
页码:67 / 76
页数:10
相关论文
共 46 条
  • [41] Tenofovir Disoproxil Fumarate-Associated Renal Dysfunction Among Adult People Living with HIV at the University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia, 2019: A Comparative Retrospective Cohort Study
    Debeb, Simachew Gidey
    Muche, Achenef Asmamaw
    Kifle, Zemene Demelash
    Sema, Faisel Dula
    HIV AIDS-RESEARCH AND PALLIATIVE CARE, 2021, 13 : 491 - 503
  • [42] Prevalence and factors associated with renal impairment in HIV-infected patients, ANRS C03 Aquitaine Cohort, France
    Deti, E. K.
    Thiebaut, R.
    Bonnet, F.
    Lawson-Ayayi, S.
    Dupon, M.
    Neau, D.
    Pellegrin, J. L.
    Malvy, D.
    Tchamgoue, S.
    Dabis, F.
    Morlat, P.
    HIV MEDICINE, 2010, 11 (05) : 308 - 317
  • [43] Cobicistat-Boosted Protease Inhibitors in HIV-Infected Patients with Mild to Moderate Renal Impairment
    McDonald, Cheryl K.
    Martorell, Claudia
    Ramgopal, Moti
    Laplante, Francois
    Fisher, Martin
    Post, Frank A.
    Liu, Yapei
    Curley, Joanne
    Abram, Michael E.
    Custodio, Joseph
    Graham, Hiba
    Rhee, Martin S.
    Szwarcberg, Javier
    HIV CLINICAL TRIALS, 2014, 15 (06): : 269 - 273
  • [44] High rate of reversibility of renal damage in a cohort of HIV-infected patients receiving tenofovir-containing antiretroviral therapy
    Bonjoch, Anna
    Echeverria, Patricia
    Perez-Alvarez, Nuria
    Puig, Jordi
    Estany, Carla
    Clotet, Bonaventura
    Negredo, Eugenia
    ANTIVIRAL RESEARCH, 2012, 96 (01) : 65 - 69
  • [45] Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study
    Domingo, Pere
    Suarez-Lozano, Ignacio
    Gutierrez, Felix
    Estrada, Vicente
    Knobel, Hernando
    Palacios, Rosario
    Antela, Antonio
    Blanco, Jose-Ramon
    Fulladosa, Xavier
    NEFROLOGIA, 2019, 39 (05): : 497 - 551
  • [46] Comparison of viral control between two tenofovir dose reduction regimens (300 mg every 48 hours versus 300 mg every 72 hours) in chronic hepatitis B patients with moderate renal impairment from tenofovir-induced renal dysfunction
    Chotiyaputta, Watcharasak
    Poosanasuwansri, Karn
    Kiattisunthorn, Kraiwiporn
    Chainuvati, Siwaporn
    Tanwandee, Tawesak
    JOURNAL OF VIRAL HEPATITIS, 2021, 28 (02) : 364 - 372